Protein Kinase C-beta Inhibitor Enzastaurin (LY317615.HCI) Enhances Radiation Control of Murine Breast Cancer in an Orthotopic Model of Bone Metastasis

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2007 Sep 7

PMID 17805485

Citations 14

Authors

Arkadiusz Z Dudek

Pawel Zwolak

Piotr Jasinski

Kaoru Terai

Nathan J Gallus

Marna E Ericson

Faris Farassati

Affiliations

Soon will be listed here.

Abstract

Radiation therapy is a widely used treatment for metastatic bone cancer, but the rapid onset of tumor radioresistance is a major problem. We investigated the radiosensitizing effect of enzastaurin, a protein kinase Cbeta (PKCbeta) inhibitor, on bone tumor growth and tumor-related pain. We found that enzastaurin enhanced the effect of ionizing radiation on cultured murine 4T1 breast cancer and murine endothelial cells, suppressing their proliferation and colony formation. Enzastaurin and ionizing radiation also induced caspase-mediated apoptosis of 4T1 cells to a greater degree than radiation alone. Enzastaurin treatment of 4T1 cells blocked the phosphorylation of PKCbeta, as well as Ras and two of its downstream effectors ERK1/2 and RAL-GTP. Using an orthotopic model of bone metastasis, we observed that a combination of enzastaurin and localized radiation treatment reduced tumor blood vessel density, bone destruction and pain compared to single modality treatment. In conclusion, we demonstrate that inhibition of PKCbeta in combination with localized radiation treatment suppresses tumor growth and alleviates pain as compared to radiation-only treatment. We also show that the radiosensitizing effect of enzastaurin is associated with suppression of tumor cell proliferation and tumor-induced angiogenesis possibly through inhibition of the Ras pathway.

Citing Articles

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.

He Y, Li J, Ding N, Wang X, Deng L, Xie Y J Exp Clin Cancer Res. 2019; 38(1):86.

PMID: 30777096 PMC: 6379963. DOI: 10.1186/s13046-019-1076-4.

Marine-derived protein kinase inhibitors for neuroinflammatory diseases.

Ning C, Wang H, Gao R, Chang Y, Hu F, Meng X Biomed Eng Online. 2018; 17(1):46.

PMID: 29690896 PMC: 5916827. DOI: 10.1186/s12938-018-0477-5.

A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.

Kilburn L, Kocak M, Decker R, Wetmore C, Chintagumpala M, Su J Neuro Oncol. 2014; 17(2):303-11.

PMID: 25431212 PMC: 4288513. DOI: 10.1093/neuonc/nou114.

Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Farren M, Carlson L, Netherby C, Lindner I, Li P, Gabrilovich D Sci Signal. 2014; 7(313):ra16.

PMID: 24550541 PMC: 4033697. DOI: 10.1126/scisignal.2004656.

A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts.

Ferron M, Settembre C, Shimazu J, Lacombe J, Kato S, Rawlings D Genes Dev. 2013; 27(8):955-69.

PMID: 23599343 PMC: 3650231. DOI: 10.1101/gad.213827.113.

References

Keyes K, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D . LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol. 2003; 53(2):133-40. DOI: 10.1007/s00280-003-0713-x. View

Sabino M, Ghilardi J, Jongen J, Keyser C, Luger N, Mach D . Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. 2002; 62(24):7343-9. View

Mach D, Rogers S, Sabino M, Luger N, Schwei M, Pomonis J . Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience. 2002; 113(1):155-66. DOI: 10.1016/s0306-4522(02)00165-3. View

Goblirsch M, Zwolak P, Clohisy D . Advances in understanding bone cancer pain. J Cell Biochem. 2005; 96(4):682-8. DOI: 10.1002/jcb.20589. View

Honore P, Luger N, Sabino M, Schwei M, Rogers S, Mach D . Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 2000; 6(5):521-8. DOI: 10.1038/74999. View

Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H . Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature. 1993; 364(6434):249-52. DOI: 10.1038/364249a0. View

Rademaker-Lakhai J, Beerepoot L, Mehra N, Radema S, van Maanen R, Vermaat J . Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2007; 13(15 Pt 1):4474-81. DOI: 10.1158/1078-0432.CCR-06-2912. View

Yoneda J, Kuniyasu H, Crispens M, Price J, Bucana C, Fidler I . Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst. 1998; 90(6):447-54. DOI: 10.1093/jnci/90.6.447. View

Mellor H, Parker P . The extended protein kinase C superfamily. Biochem J. 1998; 332 ( Pt 2):281-92. PMC: 1219479. DOI: 10.1042/bj3320281. View

10.

Sevcik M, Ghilardi J, Peters C, Lindsay T, Halvorson K, Jonas B . Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005; 115(1-2):128-41. DOI: 10.1016/j.pain.2005.02.022. View

11.

Dong Q, Bernasconi S, Lostaglio S, de Calmanovici R, Martin-Padura I, Breviario F . A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol. 1997; 17(8):1599-604. DOI: 10.1161/01.atv.17.8.1599. View

12.

Graff J, McNulty A, Hanna K, Konicek B, Lynch R, Bailey S . The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65(16):7462-9. DOI: 10.1158/0008-5472.CAN-05-0071. View

13.

Querfeld C, Rizvi M, Kuzel T, Guitart J, Rademaker A, Sabharwal S . The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol. 2006; 126(7):1641-7. DOI: 10.1038/sj.jid.5700322. View

14.

Ewing P, Wilke A, Brockhoff G, Andreesen R, Eissner G, Holler E . Isolation and transplantation of allogeneic pulmonary endothelium derived from GFP transgenic mice. J Immunol Methods. 2003; 283(1-2):307-15. DOI: 10.1016/j.jim.2003.08.004. View

15.

Kawakami Y, Nishimoto H, Kitaura J, Maeda-Yamamoto M, Kato R, Littman D . Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem. 2004; 279(46):47720-5. DOI: 10.1074/jbc.M408797200. View

16.

Liu J, Crepin M, Liu J, Barritault D, Ledoux D . FGF-2 and TPA induce matrix metalloproteinase-9 secretion in MCF-7 cells through PKC activation of the Ras/ERK pathway. Biochem Biophys Res Commun. 2002; 293(4):1174-82. DOI: 10.1016/S0006-291X(02)00350-9. View

17.

Zhang J, Anastasiadis P, Liu Y, Thompson E, Fields A . Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem. 2004; 279(21):22118-23. DOI: 10.1074/jbc.M400774200. View

18.

Black J . Protein kinase C-mediated regulation of the cell cycle. Front Biosci. 2000; 5:D406-23. DOI: 10.2741/black. View

19.

Lee S, Kwak H, Chung W, Cheong H, Kim H, Lee Z . Participation of protein kinase C beta in osteoclast differentiation and function. Bone. 2003; 32(3):217-27. DOI: 10.1016/s8756-3282(02)00976-6. View

20.

Lahn M, Kohler G, Sundell K, Su C, Li S, Paterson B . Protein kinase C alpha expression in breast and ovarian cancer. Oncology. 2004; 67(1):1-10. DOI: 10.1159/000080279. View